By using a TLR7 agonist, imiquimod (R837), as the immune adjuvant, Chen’s group reported nanosonosensitizers to allow SDT, enhanced SDT-based immunotherapy, and anti-PD-L1 for cancer treatment (Yue et al., 2019). The gene discussed is CD274; the disease is cancer.